• What’s next for account management?
  • OVID Health founder Jenny Ousbey discusses the pandemic, patient advocacy and the Patient Partnership Index
  • Gilead’s Frances Luff considers how updating NICE’s cost appraisal process and its take on value could secure fairer access to innovative treatments in the UK
  • Samantha Dawson details her experiences living with HIV
  • Gilead Sciences’ global patient engagement lead and former HIV nurse specialist Geraldine Reilly explores today’s fight against the virus – as TV series It’s A Sin brings back memories of working on the frontline during the AIDS epidemic of the 1980s and 1990s
  • Abbott’s Dr Nick West talks to PharmaTimes about going beyond intervention to improve the care of cardiovascular patients in the UK
  • Taking a look at the recent dispute between the EU Commission and AstraZeneca over the ins and outs of its contract, Stuart Evans, commercial litigation expert and partner at law firm BLM, examines what this could represent for EU/UK cross-border pharma relations
  • Digital health technologies are failing to reach their potential to boost the quality and efficiency of healthcare systems, largely because of a lack of dedicated access pathways or value assessment processes
  • After an eventful year, what’s next for the UK’s life sciences sector? Dr Kath MacKay looks into three areas for development in the years ahead
  • Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes some of the most important reforms for health and social care for nearly ten years

 

 

East Paris Pharmacy
2060 E. Paris Ave Suite 102
Grand Rapids, MI, 49546
Phone: 1 (616) 805-4601
Fax: 1 (616) 805-4826

S